GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tango Therapeutics Inc (NAS:TNGX) » Definitions » EPS (Diluted)

Tango Therapeutics (Tango Therapeutics) EPS (Diluted) : $-1.08 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Tango Therapeutics EPS (Diluted)?

Tango Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.30. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.08.

Tango Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.30. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.08.

Tango Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.30. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.08.

During the past 3 years, the average EPS without NRIGrowth Rate was -22.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, Tango Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -22.10% per year. The lowest was -22.10% per year. And the median was -22.10% per year.


Tango Therapeutics EPS (Diluted) Historical Data

The historical data trend for Tango Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tango Therapeutics EPS (Diluted) Chart

Tango Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-0.59 -0.94 -1.23 -1.08

Tango Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.32 -0.23 -0.23 -0.30

Competitive Comparison of Tango Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Tango Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tango Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tango Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Tango Therapeutics's PE Ratio falls into.



Tango Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Tango Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-101.744-0)/94.572
=-1.08

Tango Therapeutics's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-30.763-0)/104.485
=-0.29

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tango Therapeutics  (NAS:TNGX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Tango Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Tango Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Tango Therapeutics (Tango Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies.
Executives
Adam Crystal officer: See Remarks C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
John B Ketchum director TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Trv Gp Vi, Llc director 201 BROOKLINE AVE., BOSTON MA 02215
Third Rock Ventures Gp Vi, L.p. director 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Vi, L.p. director 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron Weitzman officer: Chief Medical Officer TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Marc Rudoltz officer: Chief Medical Officer TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Douglas Barry officer: See Remarks TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Third Rock Ventures Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116